Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR‐Mediated Lung Tumorigenesis

[1]  S. Waguri,et al.  GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth , 2018, Scientific Reports.

[2]  S. Elledge,et al.  A genetic interaction analysis identifies cancer drivers that modify EGFR dependency. , 2017, Genes & development.

[3]  Wei Huang,et al.  Regulation of α2B-Adrenergic Receptor Cell Surface Transport by GGA1 and GGA2 , 2016, Scientific Reports.

[4]  Jaime Rodriguez-Canales,et al.  An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer , 2016, Clinical Cancer Research.

[5]  M. Ringnér,et al.  Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History , 2014, Clinical Cancer Research.

[6]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[7]  D. Morris,et al.  The developing story of Sprouty and cancer , 2014, Cancer and Metastasis Reviews.

[8]  C. Futter,et al.  EGF receptor trafficking: consequences for signaling and cancer , 2014, Trends in cell biology.

[9]  S. Lam,et al.  YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway. , 2013, Cancer research.

[10]  Ian M. Wilson,et al.  EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk , 2013, Oncogene.

[11]  John D. Minna,et al.  Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations , 2013, Molecular Cancer Research.

[12]  H. Varmus,et al.  Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.

[13]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[14]  S. Lam,et al.  Lung Adenocarcinoma of Never Smokers and Smokers Harbor Differential Regions of Genetic Alteration and Exhibit Different Levels of Genomic Instability , 2012, PloS one.

[15]  Chris Sander,et al.  Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines , 2011, Proceedings of the National Academy of Sciences.

[16]  Kwon-Sik Park,et al.  Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. , 2011, Cancer cell.

[17]  John D. Minna,et al.  Divergent Genomic and Epigenomic Landscapes of Lung Cancer Subtypes Underscore the Selection of Different Oncogenic Pathways during Tumor Development , 2011, PloS one.

[18]  Morag Park,et al.  GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. , 2011, Developmental cell.

[19]  Yosef Yarden,et al.  Feedback regulation of EGFR signalling: decision making by early and delayed loops , 2011, Nature Reviews Molecular Cell Biology.

[20]  N. Girard,et al.  New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.

[21]  A. Iafrate,et al.  Genetically informed lung cancer medicine , 2011, The Journal of pathology.

[22]  B. Job,et al.  Genomic Aberrations in Lung Adenocarcinoma in Never Smokers , 2010, PloS one.

[23]  Hua-Chien Chen,et al.  EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. , 2010, Cancer research.

[24]  William Pao,et al.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.

[25]  Calum MacAulay,et al.  Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma , 2010, PLoS medicine.

[26]  B. Coe,et al.  FACADE: a fast and sensitive algorithm for the segmentation and calling of high resolution array CGH data , 2010, Nucleic acids research.

[27]  John D. Minna,et al.  Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy , 2010, Cancer and Metastasis Reviews.

[28]  A. Charollais,et al.  Consortin, a trans-Golgi network cargo receptor for the plasma membrane targeting and recycling of connexins. , 2010, Human molecular genetics.

[29]  T. Mok,et al.  A small step towards personalized medicine for non-small cell lung cancer. , 2009, Discovery medicine.

[30]  Calum MacAulay,et al.  Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells , 2009, PloS one.

[31]  Chris Sander,et al.  An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors , 2009, Oncogene.

[32]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[33]  John D. Minna,et al.  Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops , 2008, Cancer Prevention Research.

[34]  B. Coe,et al.  DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers , 2008, Oncogene.

[35]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[36]  H. Varmus,et al.  Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.

[37]  Bradley P. Coe,et al.  Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer , 2006, British Journal of Cancer.

[38]  J. Minna,et al.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.

[39]  Kimmo J Hatanpaa,et al.  Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. , 2006, Cancer research.

[40]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[42]  A. D. Robertson,et al.  GGA proteins bind ubiquitin to facilitate sorting at the trans-Golgi network , 2004, Nature Cell Biology.

[43]  E. Ma,et al.  Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers , 2003, Cancer.

[44]  H. Geuze,et al.  Cooperation of GGAs and AP-1 in Packaging MPRs at the Trans-Golgi Network , 2002, Science.

[45]  Wanpin Chang,et al.  Memapsin 2 (β‐secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2 , 2002, FEBS letters.

[46]  P. Madsen,et al.  The sortilin cytoplasmic tail conveys Golgi–endosome transport and binds the VHS domain of the GGA2 sorting protein , 2001, The EMBO journal.

[47]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .

[49]  J. Bonifacino.  The GGA proteins: adaptors on the move , 2004, Nature Reviews Molecular Cell Biology.